文献速递血液净化与透析

代谢组学识别维持性血液透析患者死亡相关代谢物

A Metabolomics Approach to Identify Metabolites Associated With Mortality in Patients Receiving Maintenance Hemodialysis.
PubMed 文献 · Kidney Int Rep · 2024-06-29

该研究对522例新入透析患者进行非靶向代谢组学检测,分析代谢物与1年死亡率的关联。结果发现喹啉酸和中介酸水平在1年内死亡患者中显著升高,与死亡风险独立相关。

要点

  • 喹啉酸水平在1年内死亡患者中高1.72倍(pFDR=0.009)。
  • 中介酸水平在1年内死亡患者中高1.57倍(pFDR=0.002)。
  • 9个代谢物在两种机器学习模型中均重要但limma未显著。

核心结论

  • 喹啉酸和中介酸与新入维持性血液透析患者1年死亡风险显著相关。

研究设计与样本

  • 研究纳入522例美国/加拿大新入透析(LUCID)研究参与者,检测血清代谢物。
  • 采用limma线性模型和LASSO、随机森林两种机器学习模型分析代谢物与1年死亡率的关联。

主要发现

  • 平均年龄64岁,平均透析龄35天,1年随访期间44例(8.4%)死亡。
  • 喹啉酸水平在1年内死亡患者中高1.72倍(pFDR=0.009)。
  • 中介酸水平在1年内死亡患者中高1.57倍(pFDR=0.002)。
  • 另有42个代谢物按LASSO、46个按随机森林、9个按两种模型均显示高重要性,但limma模型未显著。

临床怎么用

  • 喹啉酸和中介酸或可作为新入透析患者死亡风险的候选生物标志物。
  • 需外部验证后方可用于临床风险评估。

局限性

  • 研究结果需要外部验证。
  • 仅基于新入透析患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Uremic toxins contributing to increased risk of death remain largely unknown. We used untargeted metabolomics to identify plasma metabolites associated with mortality in patients receiving maintenance hemodialysis. METHODS: We measured metabolites in serum samples from 522 Longitudinal US/Canada Incident Dialysis (LUCID) study participants. We assessed the association between metabolites and 1-year mortality, adjusting for age, sex, race, cardiovascular disease, diabetes, body mass index, serum albumin, Kt/Vurea, dialysis duration, and country. We modeled these associations using limma, a metabolite-wise linear model with empirical Bayesian inference, and 2 machine learning (ML) models: Least absolute shrinkage and selection operator (LASSO) and random forest (RF). We accounted for multiple testing using a false discovery rate (pFDR) adjustment. We defined significant mortality-metabolite associations as pFDR < 0.1 in the limma model and metabolites of at least medium importance in both ML models. RESULTS: The mean age of the participants was 64 years, the mean dialysis duration was 35 days, and there were 44 deaths (8.4%) during a 1-year follow-up period. Two metabolites were significantly associated with 1-year mortality. Quinolinate levels (a kynurenine pathway metabolite) were 1.72-fold higher in patients who died within year 1 compared with those who did not (pFDR, 0.009), wheras mesaconate levels (an emerging immunometabolite) were 1.57-fold higher (pFDR, 0.002). An additional 42 metabolites had high importance as per LASSO, 46 per RF, and 9 per both ML models but were not significant per limma. CONCLUSION: Quinolinate and mesaconate were significantly associated with a 1-year risk of death in incident patients receiving maintenance hemodialysis. External validation of our findings is needed.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Al Awadhi S, Myint L, Guallar E, et al. A Metabolomics Approach to Identify Metabolites Associated With Mortality in Patients Receiving Maintenance Hemodialysis. Kidney Int Rep. 2024. PMID: 39291216. doi:10.1016/j.ekir.2024.06.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。